Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $22.57.
ACRV has been the topic of several recent analyst reports. LADENBURG THALM/SH SH downgraded shares of Acrivon Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. Piper Sandler raised their price target on shares of Acrivon Therapeutics from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. BMO Capital Markets restated an “outperform” rating and issued a $25.00 price target on shares of Acrivon Therapeutics in a research report on Wednesday, May 15th. HC Wainwright raised their price target on shares of Acrivon Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Finally, JMP Securities lifted their target price on shares of Acrivon Therapeutics from $14.00 to $17.00 and gave the company a “market outperform” rating in a research report on Thursday, April 25th.
Check Out Our Latest Stock Report on Acrivon Therapeutics
Hedge Funds Weigh In On Acrivon Therapeutics
Acrivon Therapeutics Trading Down 3.3 %
Acrivon Therapeutics stock opened at $7.55 on Monday. The company has a market capitalization of $233.14 million, a P/E ratio of -2.62 and a beta of 0.79. The firm’s fifty day simple moving average is $7.26 and its 200-day simple moving average is $6.71. Acrivon Therapeutics has a 1-year low of $3.19 and a 1-year high of $12.89.
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.16. On average, equities research analysts predict that Acrivon Therapeutics will post -2.47 earnings per share for the current year.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Articles
- Five stocks we like better than Acrivon Therapeutics
- Investing In Automotive Stocks
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Are Trending Stocks? Trending Stocks Explained
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.